Zoetis Inc.

Zoetis Inc.

ZTSNYSEHealthcare
$79.32
up +0.9 (+1.15%)

1-Year Price

-45.98% past year
Zoetis Inc. (ZTS) 1-year price chart: down 45.98% from $146.95 on Oct 2025 to $79.38 on Oct 2026. Closing range $69.10 to $147.53.

EquityGlimpse Score

Overall
6.1/10
Wide Moat

Strong, durable competitive advantages versus peers.

Growth
4

Valuation, profitability, financial health, dividend and sentiment scores for Zoetis Inc. (ZTS) are available to EquityGlimpse members.

Market Cap
32.78B
P/E Ratio
20.87
EPS
$6.03
52W High
$148.3
52W Low
$68.77
Volume
5.1M
Beta
0.74
Dividend Yield
1.59%
Fair value estimate: sign up to see
Is ZTS over- or undervalued? Run DCF and multiples models on EquityGlimpse.
See fair value

Key Financial Metrics

Price to Sales
5.89
Price to Book
16.75
EV/EBITDA
15.48
Free CF per Share
$5.15
Op. CF per Share
$6.55
Debt to Equity
2.85
Gross Margin
70.49%
Net Margin
28.23%

About Zoetis Inc.

Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.

CEO
Kristin C. Peck
Industry
Drug Manufacturers - Specialty & Generic
Employees
14,500
IPO Date
2013-02-01
Country
US
Website
Unlock Full Analysis

Get the complete picture on Zoetis Inc.

Sign up for EquityGlimpse to access deep fundamental data, AI reports, valuation models, and real-time tracking for ZTS and 8,500+ other stocks.

30 Years of Financials
Income statements, balance sheets, and cash flows with 70+ interactive charts
AI-Powered Analysis
Generate professional research reports with 15+ AI models
DCF Valuation
Run discounted cash flow models with customizable assumptions
Portfolio Tracking
Track real-time P&L, sector allocation, and dividend projections
Earnings Intelligence
Surprise tracking, revision momentum, and whisper estimates
Insider & Congress Trades
Monitor what insiders and Congress members are buying and selling

Starting at $8.25/month. 7-day free trial. Cancel anytime.